Latest Research And Development News

Tetratherix Limited (ASX, TTX) reports significant progress in clinical trials, strategic partnerships, and manufacturing capacity, positioning itself for near-term commercialisation and sustained innovation.

Environmental Clean Technologies Limited has completed the acquisition of Terrajoule, gaining exclusive rights to a cutting-edge soil remediation technology targeting PFAS contamination. The company also bolstered its leadership and funding to accelerate commercialisation.

AnteoTech has raised A$3.5 million through a discounted share placement to accelerate commercialisation of its advanced battery and life sciences technologies globally. The capital injection supports strategic partnerships and sales expansion in key markets including the US and India.

AML3D Limited has reported a remarkable 360% increase in customer receipts for the December 2025 quarter, driven by strong demand from the US defence sector and a robust order book of A$16.5 million for FY26. The company is accelerating its US scale-up strategy while expanding into UK and European defence markets.

Actinogen Medical has locked in a $4.3 million tranche of non-dilutive funding to support its pivotal Alzheimer’s disease trial, reinforcing its financial position as it nears critical interim and final results.

Singular Health Group has advanced its U.S. commercial footprint with the deployment of 500 new licences under its PNS contract and secured FDA clearance for its cloud-based 3DICOM MD® platform, positioning the company for significant growth.

DroneShield Limited has reported a stellar 277% revenue surge in FY2025, underpinned by a booming SaaS segment and a robust $2.09 billion sales pipeline. The company is scaling manufacturing and capitalising on new US legislation to expand its counter-drone technology footprint.

Elixir Energy has commenced drilling at the Lorelle-3 appraisal well in Queensland’s Taroom Trough, targeting significant gas resources with plans for advanced testing by mid-2026.

Anteris Technologies has completed a $90 million strategic investment from Medtronic as part of a $320 million capital raise, advancing its DurAVR transcatheter heart valve towards global commercialisation and pivotal clinical trials.

Rhythm Biosciences has begun commercialising its blood-based colorectal cancer test, ColoSTAT®, following key accreditations and validation. The company also secured a strategic partnership with NHS England and expanded its geneType™ platform globally.

Anteris Technologies has closed a $320 million capital raise, combining a $230 million public offering and a strategic private placement with Medtronic, to advance its DurAVR heart valve clinical trials and manufacturing growth.

Anteris Technologies Global Corp. has entered a material definitive agreement to raise approximately $320 million through a public offering and a strategic private placement with Medtronic’s subsidiary. The capital will support clinical trials and manufacturing expansion for its innovative heart valve technology.